Literature DB >> 17161885

UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice.

Cristiano Nazzaro1, Anna Rizzi, Severo Salvadori, Remo Guerrini, Domenico Regoli, Hanns Ulrich Zeilhofer, Girolamo Calo.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) modulates various biological functions, including nociception, via selective stimulation of the N/OFQ peptide receptor (NOP). Here we used the NOP selective antagonist UFP-101 to characterize the receptor involved in the spinal antinociceptive effects of N/OFQ evaluated in the mouse tail withdrawal assay and to investigate the mechanism underlying this action by assessing excitatory postsynaptic currents (EPSC) in laminas I and II of the mouse spinal cord dorsal horn with patch-clamp techniques. Intrathecal (i.t.) injection of N/OFQ in the range of 0.1-10 nmol produced a dose dependent antinociceptive effect, which was prevented by UFP-101, but not by naloxone. In contrast the antinociceptive effect of the mu-opioid peptide receptor agonist endomorphin-1 was blocked by naloxone but not by UFP-101. Moreover, N/OFQ and endomorphin-1 induced a significant antinociceptive effect in wild type mice while in mice knockout for the NOP receptor gene only endomorphin-1 was found to be active. In mouse spinal cord slices 1 microM N/OFQ reduced EPSC to 60+/-4% of control values. This inhibitory effect was reversed in a concentration dependent manner by UFP-101 (pA2 value 6.44). The present results demonstrate that N/OFQ-induced spinal antinociception in vivo and inhibition of spinal excitatory transmission in vitro are mediated by receptors of the NOP type.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17161885     DOI: 10.1016/j.peptides.2006.11.004

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

Review 2.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.

Authors:  A Rizzi; D D Sukhtankar; H Ding; K Hayashida; C Ruzza; R Guerrini; G Calò; M C Ko
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

4.  [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.

Authors:  S Molinari; V Camarda; A Rizzi; G Marzola; S Salvadori; E Marzola; P Molinari; J McDonald; M C Ko; D G Lambert; G Calo'; R Guerrini
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Novel strategies for the treatment of inflammatory hyperalgesia.

Authors:  Atul R Chopade; Wahid A Mulla
Journal:  Eur J Clin Pharmacol       Date:  2010-02-13       Impact factor: 2.953

Review 6.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

7.  Panicolytic-like effects caused by substantia nigra pars reticulata pretreatment with low doses of endomorphin-1 and high doses of CTOP or the NOP receptors antagonist JTC-801 in male Rattus norvegicus.

Authors:  Juliana Almeida da Silva; Audrey Franceschi Biagioni; Rafael Carvalho Almada; Renato Leonardo de Freitas; Norberto Cysne Coimbra
Journal:  Psychopharmacology (Berl)       Date:  2017-08-30       Impact factor: 4.530

8.  In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.

Authors:  Anna Rizzi; Barbara Spagnolo; Richard D Wainford; Carmela Fischetti; Remo Guerrini; Giuliano Marzola; Anna Baldisserotto; Severo Salvadori; Domenico Regoli; Daniel R Kapusta; Girolamo Calo
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

9.  Activation of spinal nociceptin receptors induces cardiovascular depression and antinociception in an independent manner in mice.

Authors:  Ching-Yi Tsai; Yan-Yuen Poon; Ya-Hui Huang; Samuel Hh Chan
Journal:  J Pain Res       Date:  2018-11-01       Impact factor: 3.133

Review 10.  Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain.

Authors:  Amal El Daibani; Tao Che
Journal:  Molecules       Date:  2022-01-18       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.